Surrozen (SRZN)
Develops multifunctional Wnt-mimetic biologics for serious retinal vascular and inflammatory eye diseases.
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the second quarter ended June 30, 2026 and provided a business update.
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright's 6th Annual Ophthalmology Investor Conference, emphasizing the company's focus on Frizzled-4 signaling, anti-VEGF activity and, in one preclinical program, IL-6 inhibition.
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the first quarter ended March 31, 2026 and provided a business update.
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of 2,020 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.
Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD)
Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. Institutional and Insider Ownership 66.6% of Surrozen shares are
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the firm's stock in a transaction that occurred on Tuesday, March 24th. The shares were bought at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update.
Tcg Crossover Gp Ii, Llc Purchases 12,374 Shares of Surrozen (NASDAQ:SRZN) Stock
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 12,374 shares of the stock in a transaction dated Thursday, March 12th. The stock was acquired at an average price of $24.99 per share, for a total transaction of $309,226.26. Following the completion of the transaction, the insider directly owned
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen.
Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review
Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 18,052 Shares of Stock
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658
Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 11,893 Shares of Stock
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 11,893 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $19.89 per share, with a total value of $236,551.77. Following the purchase, the insider directly owned
Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 11,893 Shares
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 11,893 shares of Surrozen stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77. Following the acquisition, the director directly owned 1,005,732 shares of the company's stock, valued
Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 18,052 Shares
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 18,052 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the director directly owned 1,016,658 shares of